US2017058039A1PendingUtilityA1

Anti-cd40 antibodies

61
Assignee: BOEHRINGER INGELHEIM INTPriority: Mar 31, 2010Filed: Nov 2, 2016Published: Mar 2, 2017
Est. expiryMar 31, 2030(~3.7 yrs left)· nominal 20-yr term from priority
Inventors:Rachel Rebecca BarrettScott Ronald BrodeurKeith CanadaTobias LitzenburgerSanjaya Singh
A61P 37/00A61P 7/06A61P 37/06A61P 7/04A61P 7/00A61P 9/00A61P 43/00A61P 7/10A61P 5/00A61P 3/10A61P 35/00A61P 37/02A61P 39/00A61P 29/00A61P 25/00A61P 27/00A61P 3/00A61P 21/00A61P 15/00A61P 19/04A61P 17/00A61P 21/04A61P 17/06A61P 1/00A61P 13/12A61P 15/12A61P 1/04A61P 1/16C07K 2317/33C07K 2317/24C07K 2317/92A61K 2039/505C07K 2317/94C07K 16/2878C07K 2317/732C07K 2317/73C07K 1/22C07K 2317/71C07K 2317/76C07K 2317/53C07K 2317/565C07K 2317/515A61K 9/0019C07K 2317/51C07K 14/435A61K 49/16A61K 47/42C07K 16/18A61K 48/00A61K 38/17A61K 39/395C07K 16/28C07K 14/475A61K 38/18C07K 16/22
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A prefilled syringe comprising a composition comprising a humanized antibody that specifically binds to human CD40, wherein said antibody comprises a heavy chain and a light chain, wherein the heavy chain sequence and light chain sequence are selected from the group consisting of:
 a) a heavy chain CDR1 sequence selected from the group consisting of SEQ ID NO: 9 through SEQ ID NO:11, a heavy chain CDR2 sequence selected from the group consisting of SEQ ID NO:12 through SEQ ID NO:15, and a heavy chain CDR3 sequence selected from the group consisting of SEQ ID NO:16 through SEQ ID NO:17; and   b) the light chain CDR1 sequence has a sequence selected from the group consisting of SEQ ID NO:18 through SEQ ID NO:21, a light chain CDR2 sequence of SEQ ID.   
     
     
         2 . An affinity purification composition comprising a solid phase support and a humanized antibody immobilized on the solid phase support, wherein said antibody comprises a heavy chain and a light chain, wherein the heavy chain sequence and light chain sequence are selected from the group consisting of:
 a) the heavy chain CDR1 sequence selected from the group consisting of SEQ ID NO: 9 through SEQ ID NO:11, a heavy chain CDR2 sequence selected from the group consisting of SEQ ID NO:12 through SEQ ID NO:15, and a heavy chain CDR3 sequence selected from the group consisting of SEQ ID NO:16 through SEQ ID NO:17; and   b) the light chain CDR1 sequence has a sequence selected from the group consisting of SEQ ID NO:18 through SEQ ID NO:21, a light chain CDR2 sequence of SEQ ID.   
     
     
         3 . The composition of  claim 2 , wherein the solid phase support is a Protein A resin 
     
     
         4 . A method of purifying a composition comprising human CD40 protein or a fragment thereof, the method comprising
 contacting the affinity purification composition of  claim 2  with a composition comprising a human CD40 protein or fragment thereof,   washing the solid phase support with a solvent that removes substantially all material except the human CD40 protein which is bound to the immobilized antibody, and   washing the solid phase support with a solvent that releases the human CD40 protein from the immobilized antibody.

Join the waitlist — get patent alerts

Track US2017058039A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.